A promising coronavirus vaccine being developed by Pfizer and BioNTech, a German biotechnology firm, was over 90% effective compared to a placebo injection and did not produce any safety concerns, according to an analysis by a third-party data monitoring committee.
“I would say it’s a historical moment,” said Kathrin Jansen, Pfizer’s head of vaccine research and development. “First of all, the world was faced with such a terrible situation, the pandemic, and being able in such a short time to go through what usually takes many years. Hearing that at the interim analysis we are over 90% effective – it was almost stunning to hear,” she told The Washington Post.
In the company’s nearly 44,000-person trial, only 94 cases of COVID-19 were recorded. Fewer than nine were from those who received two doses of the vaccine, according to the report.
Though there were no serious safety concerns, some infrequent side effects reported included fatigue, chills and fever, though they were more common in younger participants, the report said. (RELATED: AstraZeneca Resumes COVID Vaccine Trials)
Pfizer’s announcement is optimistic news as coronavirus cases surge in many states across the United States. The U.S. passed 10 million confirmed cases Sunday, fueled by consecutive days of over 100,000 new cases, according to a Johns Hopkins University database.
The two companies said that they plan to apply for emergency authorization from the FDA later this month once they complete two months of safety follow-up data and data on their manufacturing process. (RELATED: Pharma Execs Sign Joint Pledge Promising A Safe COVID Vaccine)
The report is especially promising since it far exceeding the FDA’s own regulatory bar, which required a vaccine to be at least 50% effective, according to The Post.
The vaccine requires two doses given three weeks apart, and the companies said that they hope to develop enough doses for 25 million people by the end of 2020 and approximately 650 million people by the end of 2021.
Contrary to earlier reports, Pfizer was one of the pharmaceutical companies aligned with Operation Warp Speed, the U.S. government’s initiative to fund and develop an effective coronavirus vaccine as soon as possible. The company signed a $1.95 billion federal contract to provide 100 million doses to Americans free of charge, assuming their vaccine proved effective.
Content created by The Daily Caller News Foundation is available without charge to any eligible news publisher that can provide a large audience. For licensing opportunities of our original content, please contact email@example.com.